SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Seufferlein Thomas))
 

Sökning: (WFRF:(Seufferlein Thomas)) > (2023) > Implementation of p...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005400naa a2200685 4500
001oai:lup.lub.lu.se:6c916092-0a8d-4d41-9a12-13efe01ec319
003SwePub
008231122s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:153285277
0247 a https://lup.lub.lu.se/record/6c916092-0a8d-4d41-9a12-13efe01ec3192 URI
0247 a https://doi.org/10.1111/joim.136982 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1532852772 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Stenzinger, Albrechtu University Hospital Heidelberg4 aut
2451 0a Implementation of precision medicine in healthcare—A European perspective
264 1c 2023
300 a 18 s.
520 a The technical development of high-throughput sequencing technologies and the parallel development of targeted therapies in the last decade have enabled a transition from traditional medicine to personalized treatment and care. In this way, by using comprehensive genomic testing, more effective treatments with fewer side effects are provided to each patient—that is, precision or personalized medicine (PM). In several European countries—such as in England, France, Denmark, and Spain—the governments have adopted national strategies and taken “top-down” decisions to invest in national infrastructure for PM. In other countries—such as Sweden, Germany, and Italy with regionally organized healthcare systems—the profession has instead taken “bottom-up” initiatives to build competence networks and infrastructure to enable equal access to PM. In this review, we summarize key learnings at the European level on the implementation process to establish sustainable governance and organization for PM at the regional, national, and EU/international levels. We also discuss critical ethical and legal aspects of implementing PM, and the importance of access to real-world data and performing clinical trials for evidence generation, as well as the need for improved reimbursement models, increased cross-disciplinary education and patient involvement. In summary, PM represents a paradigm shift, and modernization of healthcare and all relevant stakeholders—that is, healthcare, academia, policymakers, industry, and patients—must be involved in this system transformation to create a sustainable, non-siloed ecosystem for precision healthcare that benefits our patients and society at large.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng
653 a clinical trials
653 a education and training
653 a ethicolegal aspects
653 a governance
653 a patient advocacy
653 a personalized medicine
653 a precision medicine
653 a real-world evidence
7001 a Moltzen, Ejner K.4 aut
7001 a Winkler, Evau University Hospital Heidelberg4 aut
7001 a Molnar-Gabor, Fruzsinau Heidelberg University4 aut
7001 a Malek, Nisaru University Hospital of Tubingen4 aut
7001 a Costescu, Alexandruu European Commission4 aut
7001 a Jensen, Brigitte Nybo4 aut
7001 a Nowak, Frédériqueu National Institute for Health and Medical Research, France4 aut
7001 a Pinto, Carmine4 aut
7001 a Ottersen, Ole Petteru Karolinska Institute4 aut
7001 a Schirmacher, Peteru University Hospital Heidelberg4 aut
7001 a Nordborg, Jenni4 aut
7001 a Seufferlein, Thomasu University Hospital of Ulm4 aut
7001 a Fröhling, Stefanu German Cancer Research Centre4 aut
7001 a Edsjö, Andersu Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Genomic Medicine Sweden (GMS),Region Skåne4 aut0 (Swepub:lu)an7515ed
7001 a Garcia-Foncillas, Jesusu Hospital Fundación Jiménez Díaz4 aut
7001 a Normanno, Nicolau Istituto Nazionale dei Tumori4 aut
7001 a Lundgren, Bettina4 aut
7001 a Friedman, Mikaelau Karolinska Institutet,Karolinska Institute,Genomic Medicine Sweden (GMS)4 aut
7001 a Bolanos, Natacha4 aut
7001 a Tatton-Brown, Katrinau National Health Service Trust, NHS England,St George's, University of London4 aut
7001 a Hill, Sueu National Health Service Trust, NHS England4 aut
7001 a Rosenquist, Richardu Karolinska Institutet,Karolinska Institute,Genomic Medicine Sweden (GMS),Karolinska University Hospital4 aut
7102 a University Hospital Heidelbergb Heidelberg University4 org
7730 t Journal of Internal Medicineg 294:4, s. 437-454q 294:4<437-454x 0954-6820x 1365-2796
8564 u http://dx.doi.org/10.1111/joim.13698x freey FULLTEXT
8564 8u https://lup.lub.lu.se/record/6c916092-0a8d-4d41-9a12-13efe01ec319
8564 8u https://doi.org/10.1111/joim.13698
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:153285277

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy